Pb2146: characteristics and outcomes of covid-19 in patients with plasma cell disorders during the first omicron wave in beijing since december 2022: a retrospective study at a tertiary center

Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: The wave of COVID-19 infections with Omicron variant have reached the peak in December 2022 in Beijing. Aims: We described patients’ characteristics and investigated factors associated with adverse outcome during first month of the wave. Methods: Data of patients with plasma cell disorders (PCDs) infected with COVID-19 during the first month since Dec 7th was retrospectively collected. Results: One-hundred and four patients with a median age of 65 years were included. Multiple myeloma (74%, n=77) and primary amyloidosis (16.3%, n=17) were the two most common plasma cell disorders. The all-cause mortality was 4.8% (n=5), with 4 patients died of COVID-19 and 1, of the relapsed of multiple myeloma. Overall, 28(26.9%) of the patients were hospitalized, 7(25%) of whom received mechanical ventilation with 6 patients received bilevel positive airway pressure (BiPAP) and 1 with intubation. 1(3.6%) patient developed venous thromboembolism (VTE) and 7(25%) patients developed secondary fungal or bacterial infections. Severe or critical COVID-19 was developed in 17.3% of patients(n=18). In multivariate logistic analysis, age was the only independent risk factors (OR=1.14 CI 95%:1.06-1.26, p = 0.002) associated with the development of severe/critical disease, while vaccination status, immunoparesis, comorbid renal or heart disease, high-risk cytogenetics, or the application of anti-CD38 monoclonal antibody were not associated factors. In multivariate cox analysis in severe/critical group patients, albumin (HR=18.29; CI 95%: 1.82-183.44, p=0.013) and lactic dehydrogenase (HR=0.08; CI 95%: 0.01-0.65, p=0.018) were risk factors associated with COVID-19 negative conversion time. Summary/Conclusion: In patients with PCDs, the all-cause mortality was 4.8%(n=5). 18 patients (17.3%) developed severe/critical COVID-19. Only advanced age was associated with the development of severe/critical disease. In severe/critical group patients, albumin and lactic dehydrogenase were risk factors for COVID-19 negative conversion time. Keywords: Multiple myeloma, COVID-19